GlassScriptPhysician profile
Brandon S Johnson
NPI 1730162595
$3,072.26
in general payments reported to CMS, 2019-2025
37 companies · $1,056 in 2025
The $1,056 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $15.61 · 2021: $65.37 · 2022: $683 · 2023: $457 · 2024: $684 · 2025: $1,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,031 · Education: $166.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,030.56 |
| Education | $165.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $294.90 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $259.52 | 2022-2025 | Opdivo, Opdualag |
| Merck Sharp & Dohme LLC | $234.83 | 2020-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Gilead Sciences, INC. | $208.36 | 2022-2025 | Trodelvy |
| Astrazeneca Pharmaceuticals LP | $200.82 | 2022-2025 | Enhertu, Imfinzi, Lynparza |
| Celgene Corporation | $155.91 | 2023-2025 | Pomalyst, Reblozyl, Opdualag |
| Glaxosmithkline, LLC. | $116.68 | 2022-2025 | Jemperli, Zejula |
| Daiichi Sankyo INC. | $116.67 | 2024-2025 | Enhertu, Injectafer |
| Array Biopharma INC | $110.36 | 2023-2025 | Braftovi, Mektovi, Lorbrena |
| Abbott Laboratories | $107.67 | 2025 | Eterna |
| Abbvie INC. | $104.93 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $102.82 | 2024-2025 | |
| Comsort, INC | $100.00 | 2019 | |
| Amgen INC. | $96.70 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $79.87 | 2024-2025 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kite Pharma, INC. | $73.13 | 2022-2025 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $70.66 | 2022-2023 | Imbruvica, Epkinly |
| Astellas Pharma US INC | $60.31 | 2022-2025 | Vyloy, Padcev |
| Janssen Biotech, INC. | $54.83 | 2022-2025 | Darzalex, Tecvayli, Rybrevant |
| Seagen INC. | $47.96 | 2022 | |
| Beigene USA, INC. | $41.58 | 2023-2024 | Brukinsa |
| Exelixis INC. | $41.20 | 2022 | |
| Aveo Pharmaceuticals, INC. | $40.58 | 2023-2025 | Fotivda |
| Deciphera Pharmaceuticals INC. | $38.32 | 2024 | Qinlock, Tgct |
| Eisai INC. | $37.53 | 2022-2025 | |
| Springworks Therapeutics, INC. | $36.96 | 2024-2025 | Ogsiveo |
| Beone Medicines USA, INC. | $36.20 | 2025 | Brukinsa |
| Regeneron Healthcare Solutions, INC. | $34.04 | 2024 | Libtayo |
| Genzyme Corporation | $29.59 | 2023 | |
| Servier Pharmaceuticals LLC | $22.76 | 2024 | |
| Roche Diagnostics Corporation | $21.83 | 2025 | Inform Her2 Dual Ish Dna Probe Cocktail |
| Alexion Pharmaceuticals, INC. | $20.18 | 2025 | Ultomiris |
| Sobi, INC | $17.11 | 2023 | |
| Novocure INC. | $15.72 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.63 | 2021 | |
| Geron Corporation | $14.60 | 2025 | Rytelo |
| Epizyme, INC. | $11.50 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandon Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.